Abstract
Introduction: Human pluripotent stem cells (hPSCs) promise for the future of regenerative medicine. The structural and biochemical diversity associated with glycans makes them a unique type of macromolecule modification that is involved in the regulation of a vast array of biochemical events and cellular activities including pluripotency in hPSCs. The primary focus of this review article is to highlight recent advances in stem cell research from a glycobiological perspective. We also discuss how our understanding of glycans and glycosylation may help overcome barriers hindering the clinical application of hPSC-derived cells.
Areas covered: A literature survey using NCBI-PubMed and Google Scholar was performed in 2014.
Expert opinion: Regenerative medicine hopes to provide novel strategies to combat human disease and tissue injury that currently lack effective therapies. Although progress in this field is accelerating, many critical issues remain to be addressed in order for cell-based therapy to become a practical and safe treatment option. Emerging evidence suggests that protein glycosylation may significantly influence the regulation of cellular pluripotency, and that the exploitation of protein glycosylation in hPSCs and their differentiated derivatives may lead to transformative and translational discoveries for regenerative medicine. In addition, hPSCs represent a novel research platform for investigating glycosylation-related disease.
Declaration of interest
Y-C Wang is supported by the UNT Health Science Center (UNTHSC Start-up Fund for Stem Cell Laboratory). V Lin is supported by the UNT Health Science Center (Dual-degree Program) and the American Federation for Aging Research (Glenn/AFAR Scholarship). JF Loring and SE Peterson are supported by CIRM (RT1-01108, TR1-01250, TR3-05603 and CL1-00502) and NIH (R33 MH087925). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.
Notes
This box summarizes key points contained in the article.